Erasca, Inc. filings document a clinical-stage oncology issuer focused on RAS/MAPK pathway-driven cancers and common stock listed on the Nasdaq Global Select Market. Recent Form 8-K reports disclose ERAS-0015 clinical data from AURORAS-1 and JYP0015M101, Regulation FD materials, financial results, cash and marketable-securities information, and common-stock offering activity under a shelf registration statement.
Proxy materials cover annual meeting procedures, director elections, executive compensation, and stockholder voting matters. Other event reports record intellectual-property correspondence involving ERAS-0015 and provide formal updates on the company's pipeline, capital structure, and public-company governance.
Erasca, Inc. (ERAS) – Form 4 insider filing: Director Michael David Varney received a grant of 120,000 non-qualified stock options on 06/24/2025 at an exercise price of $1.45 per share. The options are subject to a one-year cliff; 100% vest on 06/24/2026, contingent on his continued service, and expire on 06/23/2035. No shares were purchased or sold; the transaction code “A” denotes an award. Following the grant, Varney beneficially owns 120,000 derivative securities, held directly. The filing does not list any other equity transactions or changes in common-stock ownership.
The option award aligns the director’s incentives with shareholder value creation, but also adds up to 120,000 potential new shares to the company’s fully diluted count once exercised.
SEC Form 4 snapshot for Erasca, Inc. (ERAS)
On June 26 2025, Director Jean I. Liu reported the receipt of a new equity award under Erasca’s incentive plan. The filing discloses 120,000 stock options (right to buy common shares) granted on June 24 2025 at an exercise price of $1.45 per share. All of the options vest in a single tranche on June 24 2026, provided Ms. Liu remains in continuous service, and they expire on June 23 2035.
- No non-derivative share transactions were reported; the disclosure relates solely to the derivative option grant.
- Following the grant, Ms. Liu shows beneficial ownership of 120,000 options, held directly.
- The transaction is coded “A” (grant without payment) and was executed outside a Rule 10b5-1 trading plan.
Option awards are routine director compensation meant to align governance incentives with shareholder value creation. The long-dated expiration (10 years) and one-year cliff vesting structure encourage strategic, long-term decision-making. The filing does not indicate any open-market buying or selling, nor does it alter Erasca’s capital structure. From an investment perspective, the event is informational rather than financially material, but it does confirm continued board engagement and standard equity-based retention practices.
Erasca, Inc. (ERAS) – Form 4 insider filing
Director Julie Hambleton received an option grant for 120,000 shares of common stock on 24 June 2025 at an exercise price of $1.45 per share. The option was issued at no cost, vests 100 % on 24 June 2026, and expires on 23 June 2035. Following the grant, Hambleton beneficially owns 120,000 derivative securities, held directly. No non-derivative share transactions were reported. The filing represents routine equity compensation for a board member and does not indicate immediate open-market buying or selling activity.
Key points from Erasca, Inc. (ERAS) Form 4
On 06/24/2025 the company granted Director Valerie Denise Harding a stock option for 120,000 common shares at an exercise price of $1.45. The transaction is coded “A” (acquisition) and is held directly by the director. According to the footnote, 100% of the option vests on 06/24/2026, provided the director remains in continuous service, and the option expires on 06/23/2035. After the grant the reporting person holds 120,000 derivative securities; no non-derivative share ownership or sales were reported.
No Rule 10b5-1 trading plan or other special conditions were indicated, and there were no accompanying purchases, sales, or exercises. The filing represents routine director compensation with limited immediate impact on Erasca’s capital structure or cash flow.
Form 4 overview: On 06/24/2025, Erasca, Inc. (ticker ERAS) granted Director Pratik S. Multani a stock option to purchase 120,000 shares of common stock at an exercise price of $1.45 per share.
Key terms:
- Vesting: 100% of the option vests on 06/24/2026, contingent on continued service.
- Expiration: 06/23/2035, providing a 10-year exercise window after vesting.
- Ownership form: Direct.
No other acquisitions, dispositions, or non-derivative holdings were reported. The filing reflects a routine equity incentive intended to align the director’s interests with shareholders rather than an open-market purchase or sale. The disclosure contains no financial performance data or forward-looking statements.
On June 26 2025, Director James Arthur Bristol submitted a Form 4 reporting an equity award from Erasca, Inc. (ERAS). The filing shows that on June 24 2025 he received 120,000 stock options with an exercise price of $1.45 per share. All of the options vest simultaneously on June 24 2026, provided he remains in continuous service, and they expire on June 23 2035. No open-market purchases or sales of common stock were disclosed, leaving Bristol’s post-transaction direct derivative holdings at 120,000 options.
The transaction constitutes an incentive grant only; it does not alter the current share float, generate cash proceeds, or affect near-term earnings. Nevertheless, the award ties the director’s future value creation to long-term share-price performance.
On 06/24/2025, Erasca, Inc. (ERAS) director Alexander W. Casdin was granted 120,000 stock options to purchase common shares at an exercise price of $1.45. The award was disclosed in a Form 4 filed on 06/26/2025 and is classified as an acquisition rather than an open-market buy.
The options vest 100% on 06/24/2026, contingent on continued board service, and will expire on 06/23/2035. Casdin now holds 120,000 derivative securities, all directly owned. Because no underlying shares were bought or sold and the grant carries no immediate cash outlay, the filing reflects routine director compensation designed to align long-term incentives rather than a directional view on near-term share price.